The stock of Danish biotech Novo Nordisk was down 2.2% Tuesday, after a study found that the company’s obesity drug Wegovy lags its main rival, Eli Lilly & Co. Inc.’s Mounjaro, in speed and magnitude of weight loss.
More Stories
With meme stocks in a lull, here’s where retail investors may turn their attention next
The dynamics that fueled the meme-stock frenzy have not gone away, according to a recent study.
Micron’s stock sentiment is weak. Here’s what could flip the script.
Micron shares have shed most of their 2024 gains, but memory pricing could improve in the coming months, Citi says.
Shohei Ohtani, the first to ever achieve 50/50, is the 352nd highest-paid player in MLB this season
That’s in part because most of his $700 million contract is deferred. Still, his stats this season are worth over...
Why Constellation Energy and Vistra shares are building on massive gains
Constellation has a new nuclear-power deal with Microsoft. Both Constellation and Vistra shares have more than doubled this year on...
Why Fed bets were so out of whack: Waller explains what put him ‘over the edge’ for a jumbo rate cut
Inflation might actually fall too far, Fed governor says.
FTC sues prescription-drug middlemen over insulin prices, says drugmakers are also ‘on notice’
Pharmacy-benefit managers owned by CVS, Cigna and UnitedHealth “artificially inflated” prices for lifesaving medications, regulator alleges.